Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
NCI-CCC Gynecologic Tumor Board Question
Questions discussed in this category
Do you consider an ovarian cancer patient who progresses on PARP inhibitor, either for treatment or maintenance, to be platinum resistant regardless of time since last platinum based chemotherapy?
Does the exact time since last platinum-based chemotherapy change your answer?
1 Answer available
How does your approach to low-risk gestational trophoblastic neoplasia differ for patients whose hCG levels plateau following initial single agent systemic therapy vs those who have a good initial response and then plateau?
1 Answer available
How do positive pelvic washings influence your decision to administer adjuvant therapy to early stage endometrial cancer who otherwise meets no criteria for adjuvant therapy?
<60y/o, grade 1 endometrioid endometrial cancer. TLH, BSO, sentinel nodes. Stage IA, focal LVSI, 20% myometrial invasion, negative sentinel nodes, ...
2 Answers available
Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?
1 Answer available
How would you proceed for a patient with metastatic gastric-type adenocarcinoma, with vaginal and inguinofemoral disease only, who experiences complete response to her vaginal tumor but residual inguinal disease?
History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...
2 Answers available
How would you adjust therapy for a patient with high risk, stage III choriocarcinoma (lung mets) in the context of renal insufficiency (Cr 3.8)?
1 Answer available
How would you manage a patient with recurrent granulosa tumor following secondary, R0 cytoreduction, and negative inhibins postoperatively?
Primary, R0 debulking in 2019, stage IA. Low volume recurrence, now again optimally cytoreduced.
1 Answer available
After an optimal tertiary cytoreduction for recurrent granulosa cell tumor previously treated with BEP and hormonal therapy, would you recommend systemic chemotherapy?
Initial diagnosis was 15+ years ago
2 Answers available
How would you treat/counsel a patient with Stage IB3 SCC of the cervix who is 18 weeks pregnant and desires to maintain pregnancy?
1 Answer available
When might you recommend adjuvant chemotherapy for fully staged/resected stage IA clear cell ovarian carcinoma?
2 Answers available
What adjuvant therapy do you recommend for comprehensively staged, stage II, FIGO grade 3 deeply invasive endometrial cancer?
1 Answer available
How would you manage a clinically inoperable, stage IIIB, MMR deficient uterine cancer?
Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement. ER/PR and HER2 testing are pending.
1 Answer available
9295
12957
9562
10094
10208
9860
9029
9540
9449
9023
8745
9028
Papers discussed in this category
Gynecologic oncology, 2014-11
Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
Practical radiation oncology, 2019
Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.
Gynecologic oncology, 2019-06
Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
Gynecol Oncol, 2021 Mar 05
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Related Topics
Gynecologic Cancers
NCI-CCC Tumor Board Question
Medical Oncology
Endometrial Cancer
University of Pennsylvania
Johns Hopkins
Radiation Oncology
University of Utah
University of Florida
Ovarian Cancer